Neuroprotective effects of Vitis vinifera extract on prediabetic mice induced by a high-fat diet.
10.3904/kjim.2013.28.5.579
- Author:
Heung Yong JIN
1
;
Youn Soo CHA
;
Hong Sun BAEK
;
Tae Sun PARK
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine and Research institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju, Korea. pts@jbnu.ac.kr
- Publication Type:Original Article
- Keywords:
Antioxidants;
Diet, high-fat;
Peripheral nervous system diseases;
Prediabetic state;
Vitis vinifera grape seed extract
- MeSH:
Animals;
Antioxidants/*pharmacology;
Biological Markers/blood;
Blood Glucose/drug effects/metabolism;
Body Weight/drug effects;
Diabetic Neuropathies/blood/etiology/pathology/*prevention & control;
*Diet, High-Fat;
Disease Models, Animal;
Dose-Response Relationship, Drug;
Epidermis/*innervation;
Grape Seed Extract/*pharmacology;
Lipids/blood;
Male;
Mice;
Mice, Inbred C57BL;
Neuroprotective Agents/*pharmacology;
Peripheral Nerves/*drug effects/pathology;
Phytotherapy;
Plants, Medicinal;
Prediabetic State/blood/*drug therapy/etiology;
Time Factors;
*Vitis
- From:The Korean Journal of Internal Medicine
2013;28(5):579-586
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Vitis vinifera grape seed extract (VVE) contains oligomeric proanthocyanidins that show antioxidant and free radical-scavenging activities. We evaluated VVE for its neuroprotective effect in prediabetic mice induce by a high-fat diet (HD). METHODS: Mice were divided into four groups according to VVE dose: those fed a normal diet (ND; n = 10), HD (n = 10), HD with 100 mg/kg VVE (n = 10), and HD with 250 mg/kg VVE (n = 10). After 12 weeks, immunohistochemical analyses were carried out using a polyclonal antibody against antiprotein gene product 9.5 (protein-gene-product, 9.5), and intraepidermal innervation was subsequently quantified as nerve fiber abundance per unit length of epidermis (intraepidermal nerve fiber, IENF/mm). RESULTS: Daily administration of VVE at doses of 100 or 250 mg/kg for 12 weeks protected HD mice from nerve fiber loss compared to untreated mice, as follows (IENF/mm): controls (40.95 +/- 5.40), HD (28.70 +/- 6.37), HD with 100 mg/kg (41.14 +/- 1.12), and HD with 250 mg/kg (48.98 +/- 7.01; p < 0.05, HD with VVE vs. HD). CONCLUSIONS: This study provides scientific support for the therapeutic potential of VVE in peripheral neuropathy in an HD mouse model. Our results suggest that VVE could play a role in the management of peripheral neuropathy, similar to other antioxidants known to be beneficial for diabetic peripheral neuropathy.
